Dinesh Thakur on Ranbaxy US FDA case

Mint 2018-02-16

Views 1

Dinesh Thakur, former Ranbaxy director and the whistle in the case, speaks to Mint about the implications of the order for the Indian generic drug industry. Ranbaxy had plead guilty of making fradulent statements to the US FDA.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
From the Newsroom| Fourth Ranbaxy plant under FDA scrutiny
play
03:58

From the Newsroom| Fourth Ranbaxy plant under FDA scrutiny
Ranbaxy accused of gaming FDA rules to thwart rival drug makers
play
01:17

Ranbaxy accused of gaming FDA rules to thwart rival drug makers
From the Newsroom: US judge dismisses harassment case against Infosys
play
04:05

From the Newsroom: US judge dismisses harassment case against Infosys
Ranbaxy to take $1 billion hit on derivatives
play
01:04

Ranbaxy to take $1 billion hit on derivatives
USFDA issues import alert for Ranbaxy Mohali facilities
play
02:24

USFDA issues import alert for Ranbaxy Mohali facilities
Sun Pharma-Ranbaxy deal in CCI crosshairs
play
02:41

Sun Pharma-Ranbaxy deal in CCI crosshairs
Ranbaxy to pay $40 million to settle Texas probe on drug pricing
play
00:52

Ranbaxy to pay $40 million to settle Texas probe on drug pricing
Sun Pharma acquires Ranbaxy Labs
play
07:44

Sun Pharma acquires Ranbaxy Labs
Mark to market on Ranbaxy
play
01:23

Mark to market on Ranbaxy
FDA charges data integrity issues in Wockhardt factories
play
03:33

FDA charges data integrity issues in Wockhardt factories
Interview with the BJP's Anurag Thakur
play
02:18

Interview with the BJP's Anurag Thakur
From The Newsroom: Market for planes to expand: Dinesh Keskar
play
04:44

From The Newsroom: Market for planes to expand: Dinesh Keskar